CN101184506B - 用于调节超稳定化的c-met的方法和组合物 - Google Patents

用于调节超稳定化的c-met的方法和组合物 Download PDF

Info

Publication number
CN101184506B
CN101184506B CN2006800183951A CN200680018395A CN101184506B CN 101184506 B CN101184506 B CN 101184506B CN 2006800183951 A CN2006800183951 A CN 2006800183951A CN 200680018395 A CN200680018395 A CN 200680018395A CN 101184506 B CN101184506 B CN 101184506B
Authority
CN
China
Prior art keywords
met
antibody
ser
leu
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800183951A
Other languages
English (en)
Chinese (zh)
Other versions
CN101184506A (zh
Inventor
莫妮卡·康-贝尔特伦
迪内利·M·威克拉马辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101184506(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN101184506A publication Critical patent/CN101184506A/zh
Application granted granted Critical
Publication of CN101184506B publication Critical patent/CN101184506B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800183951A 2005-03-25 2006-03-24 用于调节超稳定化的c-met的方法和组合物 Active CN101184506B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25
US60/665,482 2005-03-25
PCT/US2006/010850 WO2006104911A2 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Publications (2)

Publication Number Publication Date
CN101184506A CN101184506A (zh) 2008-05-21
CN101184506B true CN101184506B (zh) 2013-07-17

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800183951A Active CN101184506B (zh) 2005-03-25 2006-03-24 用于调节超稳定化的c-met的方法和组合物

Country Status (17)

Country Link
US (2) US7615529B2 (enExample)
EP (1) EP1868648B1 (enExample)
JP (2) JP2008535821A (enExample)
KR (1) KR20080000613A (enExample)
CN (1) CN101184506B (enExample)
AU (1) AU2006229989B2 (enExample)
BR (1) BRPI0611468A2 (enExample)
CA (1) CA2599988A1 (enExample)
ES (1) ES2539790T3 (enExample)
IL (1) IL185708A (enExample)
MX (1) MX2007011652A (enExample)
NO (1) NO20075412L (enExample)
NZ (1) NZ561211A (enExample)
RU (1) RU2404193C2 (enExample)
SG (1) SG159547A1 (enExample)
WO (1) WO2006104911A2 (enExample)
ZA (1) ZA200707953B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868648B1 (en) * 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
AU2009221808A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and EGFR antagonists
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
CA2757531A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
SG175078A1 (en) * 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
CA2780143A1 (en) * 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
KR101814571B1 (ko) 2010-03-10 2018-01-04 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
MX2013004476A (es) * 2010-10-20 2013-06-28 Oxford Biotherapeutics Ltd Anticuerpos.
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
CN104066748A (zh) * 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
MX2016006219A (es) 2013-11-14 2016-10-28 Endocyte Inc Compuestos para tomografia por emision de positrones.
WO2015139046A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
KR20170136536A (ko) 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
RS61204B1 (sr) 2016-09-14 2021-01-29 Abbvie Biotherapeutics Inc Anti-pd-1 antitela
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
CN112703004B (zh) 2018-07-15 2025-02-14 雷诺瓦罗生物制药公司 使用重组树突状细胞用于癌症治疗的方法和组合物
CA3131654A1 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
WO2020236808A1 (en) 2019-05-20 2020-11-26 Endocyte, Inc. Methods for preparing psma conjugates
WO2021055350A1 (en) 2019-09-16 2021-03-25 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN114478788B (zh) 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE69739276D1 (de) 1996-04-05 2009-04-09 Antonio Giordano Methoden zur diagnose und prognose von krebs
ATE465257T1 (de) 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
ATE425463T1 (de) * 2003-06-06 2009-03-15 Genentech Inc Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
RU2007139516A (ru) 2005-03-25 2009-04-27 Дженентек, Инк. (Us) Мутации с-мет при раке легких
EP1868648B1 (en) 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Patrick C. Ma et al.Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer.《Cancer Research》.2005,第65卷(第4期),1479-1488. *

Also Published As

Publication number Publication date
HK1109075A1 (en) 2008-05-30
KR20080000613A (ko) 2008-01-02
CA2599988A1 (en) 2006-10-05
US8536118B2 (en) 2013-09-17
AU2006229989A1 (en) 2006-10-05
CN101184506A (zh) 2008-05-21
WO2006104911A3 (en) 2007-02-22
SG159547A1 (en) 2010-03-30
JP2008535821A (ja) 2008-09-04
AU2006229989B2 (en) 2012-02-02
RU2404193C2 (ru) 2010-11-20
NZ561211A (en) 2011-03-31
WO2006104911A2 (en) 2006-10-05
BRPI0611468A2 (pt) 2010-09-08
ZA200707953B (en) 2009-06-24
EP1868648A2 (en) 2007-12-26
EP1868648B1 (en) 2015-04-15
US20060270594A1 (en) 2006-11-30
IL185708A (en) 2014-11-30
US7615529B2 (en) 2009-11-10
US20100028337A1 (en) 2010-02-04
NO20075412L (no) 2007-12-21
ES2539790T3 (es) 2015-07-06
IL185708A0 (en) 2008-01-06
MX2007011652A (es) 2007-11-14
JP2012232979A (ja) 2012-11-29
RU2007139452A (ru) 2009-04-27

Similar Documents

Publication Publication Date Title
CN101184506B (zh) 用于调节超稳定化的c-met的方法和组合物
US20220204640A1 (en) Compositions and methods for the diagnosis and treatment of tumor
US20180344864A1 (en) Compositions and methods for the diagnosis and treatment of tumor
CN102985113A (zh) 用于肿瘤诊断和治疗的组合物和方法
JP2014503180A (ja) 突然変異体スムースンド及びその使用方法
CN104284677A (zh) 用于肿瘤诊断和治疗的组合物和方法
CN107090045A (zh) 用于肿瘤诊断和治疗的组合物和方法
JP5819308B2 (ja) マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
HK1109075B (en) Methods and compositions for modulating hyperstabilized c-met
CN101595130B (zh) 用于肿瘤诊断和治疗的组合物和方法
HK1178074B (en) Compositions and methods for the diagnosis and treatment of tumor
HK1192891B (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
HK1192891A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
HK1192890B (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
HK1174342A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
HK1178181A (en) Compositions and methods for the diagnosis and treatment of tumor
HK1192890A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
HK1134098B (en) Antibodies binding to the tumour associated antigen tat10772 for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant